Market Cap: $96 million| Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally.
On June 21, 2022, Cannell Capital (12.94%) had a call with Robert Cascella, Chairman of the Board of the Company, during which it requested the appointment of a certain board member. In the opinion of Cannell Capital, the addition of this candidate would benefit all owners of the company because: (i) his domicile is in the same city as the Company; (ii) he enjoys a predilection to buy a lot of stock in the Company; and (iii) he manifests robust experience and execution in the medical technology industry. From his appointment as CEO of his predecessor company in 2010 to its purchase, the stock of this company appreciated 1,000%. Source
Commentaires